Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $5.83.

Several research analysts have recently issued reports on the stock. Alliance Global Partners reiterated a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Weiss Ratings downgraded shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Finally, Lake Street Capital decreased their price objective on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a report on Friday, August 14th.

Sensus Healthcare Price Performance

Shares of NASDAQ:SRTS opened at $2.91 on Friday. Sensus Healthcare has a 1-year low of $2.66 and a 1-year high of $5.49. The business has a fifty day moving average price of $3.11 and a 200-day moving average price of $3.38. The company has a market capitalization of $47.90 million, a PE ratio of -3.10 and a beta of 1.13.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The firm had revenue of $2.29 million during the quarter, compared to the consensus estimate of $4.60 million.

Insider Activity at Sensus Healthcare

In other Sensus Healthcare news, Director Eric Sachetta purchased 27,304 shares of the firm’s stock in a transaction dated Monday, August 31st. The stock was purchased at an average price of $3.54 per share, for a total transaction of $96,656.16. Following the completion of the purchase, the director directly owned 294,784 shares of the company’s stock, valued at $1,043,535.36. This trade represents a 10.21% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders acquired 120,171 shares of company stock valued at $405,230. 10.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sensus Healthcare

Institutional investors and hedge funds have recently bought and sold shares of the stock. EP Wealth Advisors LLC purchased a new position in Sensus Healthcare during the 2nd quarter valued at approximately $49,000. BlackRock Inc. bought a new stake in Sensus Healthcare during the 2nd quarter valued at about $252,000. Bank of New York Mellon Corp purchased a new stake in Sensus Healthcare in the 2nd quarter valued at about $303,000. Finally, North Star Investment Management Corp. purchased a new stake in Sensus Healthcare in the 1st quarter valued at about $500,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical device company focused on noninvasive treatments for dermatologic and oncologic conditions. The company develops and commercializes superficial radiation therapy systems designed to deliver low-energy X-rays to targeted areas of the skin while limiting exposure to surrounding tissue.

Its principal products include the SRT-100 and SRT-100 Vision systems, which are used primarily to treat non-melanoma skin cancers such as basal cell and squamous cell carcinomas, as well as certain keloid scars.